Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Pharmaceuticals, Qiagen


Genaissance Pharmaceuticals has launched its Familion test for cardiac channelopathies. The test confirms the presence of mutations known to cause these life-threatening conditions, which include Long QT and Brugada Syndromes. There are five of these mutations.

Before Familion was released, cardiologists identified individuals at risk for channelopathies by performing an electrocardiogram — which is “difficult and may be overlooked,” Genaissance said.

Besides developing the test as a diagnostic tool for pediatric cardiologists and electrophysiologists, Genaissance said it hopes to sell the product along with the company’s haplotype technology to drug makers, which would use the test in clinical trials as a way to avoid drug-induced Long QT problems.

Drugs known to increase an individual’s risk of developing a prolonged QT interval include certain antibiotics, antidepressants, antihistamines, diuretics, cardiac drugs, antihypercholesterolemia drugs, insulin, antifungals, and antipsychotics.

Read more about the Familion test in the 4/8/04 PGx Reporter.

Qiagen has released Version 3.0 of its Array-Ready Oligo Set for the rat genome. The product contains 26,962 70-mer probes, representing 22,012 genes and 27,044 gene transcripts, the company said.

The new Rat AROS uses data from the Ensembl Rat 19.3b.2 database, which is based on the Rat Genome Sequencing Project.


Filed under

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.